How much has biomodal raised?

biomodal disclosed a $21M Series B led by GV in 2016, with support from Sequoia and other investors. In 2021, while still Cambridge Epigenetix, it announced an $88M Series D led by Temasek with participation from Third Point and existing investors including GV, New Science Ventures, Ahren, and Sequoia.

The investor or owner set is described in the public capital history. Sequoia provenance is included where Sequoia lists biomodal in its official company database, and this profile avoids filling undisclosed investor allocations.

For biomodal, valuation is either public-market/acquisition based or not disclosed. The responsible interpretation is to use disclosed transaction values and status, not extrapolated private marks.

Profitability and IPO timing are not disclosed unless public filings say otherwise. Sellers should use stage, ownership, and operating milestones as budget signals.

The funding or ownership context points to active budgets in the areas directly tied to Life sciences tools: product, compliance, infrastructure, data, and go-to-market systems. A useful pitch should map to measurable operational outcomes rather than generic growth claims.